2024 Pfizer Grant for High Impact Research in Inflammatory Skin Diseases

Open call for proposals 2024:

Canadian Dermatology Foundation 2024 Pfizer Grant for High Impact Research in Inflammatory Skin Diseases

The Canadian Dermatology Foundation 2024 Pfizer Grant for High Impact Research in Inflammatory Skin Diseases is a $100,000, one year research grant that will be awarded to a team or individual for mature research projects with a focus on inflammatory skin conditions: Atopic Dermatitis, Alopecia Areata and Vitiligo.  Research project must significantly impact the understanding of disease pathogenesis and/or enhance patient care. The granting period is one year, and the project must be mature and potentially ready for knowledge dissemination within 1-2 years.

Submission deadline is Friday, May 31, 2024 at 11:59pm ET.

Eligibility

Primary Investigator (PI) must hold an appointment at a dermatology academic unit of a Canadian University (dermatology department or division). PIs who hold no other active CDF grant, or hold a grant where funding expired in 2024, are considered eligible to apply in 2024.  If you are a Primary Investigator with a current CDF grant, you may not apply.

Click here to apply for the Canadian Dermatology Foundation 2024 Pfizer Grant for High Impact Research in Inflammatory Skin Diseases

Detailed Research Proposal

Applicants should provide a clear, concise description of their research proposal including purpose/hypothesis, related previous work and preliminary/supporting data, methods, expected outcomes and significance, and the contributions of primary investigator and co-investigators. They should reference relevant published literature.

The major assessment criteria are novelty, feasibility and impact. In this regard:

  • Please include the research plan explaining how this project can be brought to completion within a timeframe of 1-2 years.
  • Explain why this project is innovative and high-impact in the area of inflammatory skin diseases.

Adhering to a maximum of seven pages is mandatory. The text is limited to a 11 point font (Times, Arial, Calibri, or Helvetica) with a minimum margin width of 1 inch on all sides.

Page limit excludes references, figures, and tables, which can be included as appendices to the main grant proposal. No additional text beyond figure and table legends can be added to the appendix. Do NOT include any publication reprints in the appendices. PLEASE ASSEMBLE THE PROPOSAL AND ANY APPENDICES INTO ONE FILE FOR UPLOAD.

Applications where the grant proposal exceeds the page limit or where publication reprints have been included in the appendices risk being disqualified from the review and funding process.

Budget

Grants are for one year, maximum $100,000. Please DO NOT include knowledge dissemination cost in the budget. Upon successful completion of the project, the research team will be eligible for additional funding of up to $30,000 for development of peer reviewed publications and materials to facilitate knowledge dissemination, public education, and awareness of the diseases and the research.

 Peer Review Process

The CDF adheres to CIHR grant review principles. Each grant undergoes evaluation by two independent reviewers: the primary and secondary. The primary reviewer presents the score and justification to the panel, followed by input from the secondary reviewer. Post additional discussion, each panel member assigns a score, with the average determining the final ranking for project assessment. This process ensures a meticulous evaluation aligned with rigorous medical research standards. The criteria for grant assessment can be accessed here. The review panel, presided over by the CDF Scientific Chair, is tasked with safeguarding the fairness of the review process, with the chair refraining from participating in voting. To reinforce impartiality, non-voting observers will be invited, representing key stakeholders.

We expect to announce the successful grant recipient during the 2024 CDA Conference in June in Ottawa.